ArticleNeurology2023
In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using [18F]PI-2620 PET.
Open access · hybridAbstract read
In one paragraph
Article in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Diagnosing autoimmune encephalitis in psychiatry: clinical recommendations and unresolved challenges from the GENERATE network.Molecular psychiatry · 2026Review
- Severe sleep-related hypoventilation in antibody-positive and antibody-negative autoimmune encephalitis: an emergency.The European respiratory journal · 2026Article
- Brain atrophy patterns in anti-IgLON5 disease.Brain : a journal of neurology · 2026Article
- Case Report: PET/CT assessment of immunomodulatory therapy in anti-IgLON5 encephalitis with sleep apnea.Frontiers in neuroscience · 2026Article
- Patterns of Tau pathology in patients with anti-IgLON5 disease visualized by Florzolotau (18F) PET.Journal of neurology · 2025Article
- Anti-IgLON5 Disease 10 Years Later: What We Know and What We Do Not Know.Neurology(R) neuroimmunology & neuroinflammation · 2025Review
- Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy.Acta neuropathologica · 2024Article
- Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies.Journal of neurology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Hendrik TheisFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0003-4661-5994
Gérard N BischofFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0002-4366-5171
Norbert BrüggemannFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Justina DargvainieneFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0009-0002-4114-3748
Alexander DrzezgaFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0001-6018-716X
Thomas GrüterFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0001-8927-9818
Jan LewerenzFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0002-9272-529X
Frank LeypoldtFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0002-8972-515X
Bernd NeumaierFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0001-5425-3116
Klaus-Peter WandingerFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.ORCID 0000-0002-5483-4276
Ilya AyzenbergFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Thilo van EimerenFrom the Multimodal Neuroimaging Group (H.T., G.N.B., A.D., T.v.E.), Department of Nuclear Medicine, and Department of Neurology (H.T., T.v.E.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine (INM-2), Forschungszentrum J̈lich; Department of Neurology (N.B.), Faculty of Medicine and University Hospital Schleswig Holstein (Lübeck), University of Lübeck; Institute of Clinical Chemistry (J.D., F.L., K.-P.W.), University Hospital Schleswig Holstein, Kiel/Lübeck German Center for Neurodegenerative Diseases (DZNE) (A.D.), Bonn-Cologne; Department of Neurology (T.G., I.A.), Faculty of Medicine and St. Josef-Hospital, Ruhr University Bochum; Department of Neurology (J.L.), Faculty of Medicine and University Hospital Ulm, Ulm University; Department of Neurology (F.L.), Faculty of Medicine and University Hospital Schleswig Holstein, Kiel University; Nuclear Chemistry (B.N.), Institute for Neuroscience and Medicine (INM-5), Forschungszentrum Jülich; and Institute of Radiochemistry and Experimental Molecular Imaging (B.N.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany. thilo.van-eimeren@uk-koeln.de.
University Hospital Cologne · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAnti-IgLON5 disease is a recently discovered neurologic disorder combining autoimmunity and neurodegeneration. Core manifestations include sleep disorders, bulbar symptoms, gait abnormalities, and cognitive dysfunction, but other presentations have been reported. Hallmarks are autoantibodies targeting the neuronal surface protein IgLON5, a strong human leukocyte antigen system Class II association, and brainstem and hypothalamus-dominant tau deposits. The purpose of this cohort study was to visualize tau deposition in vivo with the second-generation tau-PET tracer.
methodsA cohort of 4 patients with anti-IgLON5 disease underwent a dynamic PET scan with [18F]PI-2620. One patient received a follow-up scan. Z-deviation maps and a 2-sample
resultsPatients demonstrated increased [18F]PI2620 tau binding potentials in the pons, dorsal medulla, and cerebellum. The longitudinal scan after 28 months showed an increase of tracer uptake in the medulla despite immunotherapy. Higher antibody titers and neurofilament light chain correlated with higher tracer retention. DISCUSSION: The results indicate that tau depositions in anti-IgLON5 disease can be visualized with [18F]PI-2620 and might correlate with the extent of disease. For validation, a larger longitudinal study is necessary.
Indexed as
Alzheimer DiseaseParasomniasSleep Apnea, ObstructiveCell Adhesion Molecules, NeuronalCohort StudiesHumansLongitudinal StudiesPositron-Emission TomographyPyridinestau ProteinsCell Adhesion Molecules, NeuronalIgLON5 protein, humanPI-2620Pyridinestau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.